Research ExplorerPublicationsHealth-related quality-of-life results from the phase 3 OPTI...

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Standard

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. / Weisel, Katja; Dimopoulos, Meletios; Moreau, Philippe; Yagci, Munci; Larocca, Alessandra; Kanate, Abraham S; Vural, Filiz; Cascavilla, Nicola; Basu, Supratik; Johnson, Peter; Byeff, Peter; Hus, Marek; Rodríguez-Otero, Paula; Muelduer, Ercan; Anttila, Pekka; Hayden, Patrick J; Krauth, Maria-Theresa; Lucio, Paulo; Ben-Yehuda, Dina; Mendeleeva, Larisa; Guo, Shien; Yu, Xin; Grote, Lara; Biyukov, Tsvetan; Dhanasiri, Sujith; Richardson, Paul.

In: LEUKEMIA LYMPHOMA, Vol. 61, No. 8, 08.2020, p. 1850-1859.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Weisel, K, Dimopoulos, M, Moreau, P, Yagci, M, Larocca, A, Kanate, AS, Vural, F, Cascavilla, N, Basu, S, Johnson, P, Byeff, P, Hus, M, Rodríguez-Otero, P, Muelduer, E, Anttila, P, Hayden, PJ, Krauth, M-T, Lucio, P, Ben-Yehuda, D, Mendeleeva, L, Guo, S, Yu, X, Grote, L, Biyukov, T, Dhanasiri, S & Richardson, P 2020, 'Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma', LEUKEMIA LYMPHOMA, vol. 61, no. 8, pp. 1850-1859. https://doi.org/10.1080/10428194.2020.1747066

APA

Weisel, K., Dimopoulos, M., Moreau, P., Yagci, M., Larocca, A., Kanate, A. S., Vural, F., Cascavilla, N., Basu, S., Johnson, P., Byeff, P., Hus, M., Rodríguez-Otero, P., Muelduer, E., Anttila, P., Hayden, P. J., Krauth, M-T., Lucio, P., Ben-Yehuda, D., ... Richardson, P. (2020). Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. LEUKEMIA LYMPHOMA, 61(8), 1850-1859. https://doi.org/10.1080/10428194.2020.1747066

Vancouver

Weisel K, Dimopoulos M, Moreau P, Yagci M, Larocca A, Kanate AS et al. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. LEUKEMIA LYMPHOMA. 2020 Aug;61(8):1850-1859. https://doi.org/10.1080/10428194.2020.1747066

Bibtex

@article{cc6041bd6bb14166b3e1fde355a11cf5,
title = "Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma",
abstract = "In the randomized phase-3 OPTIMISMM study, the addition of pomalidomide to bortezomib and low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival (PFS) in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM), including lenalidomide refractory patients. Here, we report health-related quality of life (HRQoL) results from this trial. Patients received PVd or Vd in 21-day cycles until disease progression or discontinuation. HRQoL was assessed using the EORTC QLQ-C30, QLQ-MY20, and EQ-5D-3L instruments on day 1 of each treatment cycle. Mean score changes for global QoL, physical functioning, fatigue, side effects of treatment domains, and EQ-5D-3L index were generally stable over time across treatment arms. The proportion of patients who experienced clinically meaningful worsening in global QoL and other domains of interest was similar. These HRQoL results with PVd along with previously demonstrated improvement in PFS vs Vd continue to support its use in patients with RRMM.",
author = "Katja Weisel and Meletios Dimopoulos and Philippe Moreau and Munci Yagci and Alessandra Larocca and Kanate, {Abraham S} and Filiz Vural and Nicola Cascavilla and Supratik Basu and Peter Johnson and Peter Byeff and Marek Hus and Paula Rodr{\'i}guez-Otero and Ercan Muelduer and Pekka Anttila and Hayden, {Patrick J} and Maria-Theresa Krauth and Paulo Lucio and Dina Ben-Yehuda and Larisa Mendeleeva and Shien Guo and Xin Yu and Lara Grote and Tsvetan Biyukov and Sujith Dhanasiri and Paul Richardson",
year = "2020",
month = aug,
doi = "10.1080/10428194.2020.1747066",
language = "English",
volume = "61",
pages = "1850--1859",
journal = "LEUKEMIA LYMPHOMA",
issn = "1042-8194",
publisher = "informa healthcare",
number = "8",

}

RIS

TY - JOUR

T1 - Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

AU - Weisel, Katja

AU - Dimopoulos, Meletios

AU - Moreau, Philippe

AU - Yagci, Munci

AU - Larocca, Alessandra

AU - Kanate, Abraham S

AU - Vural, Filiz

AU - Cascavilla, Nicola

AU - Basu, Supratik

AU - Johnson, Peter

AU - Byeff, Peter

AU - Hus, Marek

AU - Rodríguez-Otero, Paula

AU - Muelduer, Ercan

AU - Anttila, Pekka

AU - Hayden, Patrick J

AU - Krauth, Maria-Theresa

AU - Lucio, Paulo

AU - Ben-Yehuda, Dina

AU - Mendeleeva, Larisa

AU - Guo, Shien

AU - Yu, Xin

AU - Grote, Lara

AU - Biyukov, Tsvetan

AU - Dhanasiri, Sujith

AU - Richardson, Paul

PY - 2020/8

Y1 - 2020/8

N2 - In the randomized phase-3 OPTIMISMM study, the addition of pomalidomide to bortezomib and low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival (PFS) in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM), including lenalidomide refractory patients. Here, we report health-related quality of life (HRQoL) results from this trial. Patients received PVd or Vd in 21-day cycles until disease progression or discontinuation. HRQoL was assessed using the EORTC QLQ-C30, QLQ-MY20, and EQ-5D-3L instruments on day 1 of each treatment cycle. Mean score changes for global QoL, physical functioning, fatigue, side effects of treatment domains, and EQ-5D-3L index were generally stable over time across treatment arms. The proportion of patients who experienced clinically meaningful worsening in global QoL and other domains of interest was similar. These HRQoL results with PVd along with previously demonstrated improvement in PFS vs Vd continue to support its use in patients with RRMM.

AB - In the randomized phase-3 OPTIMISMM study, the addition of pomalidomide to bortezomib and low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival (PFS) in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM), including lenalidomide refractory patients. Here, we report health-related quality of life (HRQoL) results from this trial. Patients received PVd or Vd in 21-day cycles until disease progression or discontinuation. HRQoL was assessed using the EORTC QLQ-C30, QLQ-MY20, and EQ-5D-3L instruments on day 1 of each treatment cycle. Mean score changes for global QoL, physical functioning, fatigue, side effects of treatment domains, and EQ-5D-3L index were generally stable over time across treatment arms. The proportion of patients who experienced clinically meaningful worsening in global QoL and other domains of interest was similar. These HRQoL results with PVd along with previously demonstrated improvement in PFS vs Vd continue to support its use in patients with RRMM.

U2 - 10.1080/10428194.2020.1747066

DO - 10.1080/10428194.2020.1747066

M3 - SCORING: Journal article

C2 - 32268815

VL - 61

SP - 1850

EP - 1859

JO - LEUKEMIA LYMPHOMA

JF - LEUKEMIA LYMPHOMA

SN - 1042-8194

IS - 8

ER -